Cost of Treatment in a US Commercially Insured, HIV-1–Infected Population

Open Access

Peer-reviewed

Research Article

Caitlyn T. Solem,

Affiliation Pharmerit International, Bethesda, Maryland, United States of America
⨯
Sonya J. Snedecor ,

* E-mail: ssnedecor@pharmerit.com

Affiliation Pharmerit International, Bethesda, Maryland, United States of America
⨯
Alexandra Khachatryan,

Affiliation Pharmerit International, Bethesda, Maryland, United States of America
⨯
Katherine Nedrow,

Affiliation Pfizer Inc, Groton, Connecticut, United States of America
⨯
Margaret Tawadrous,

Affiliation Pfizer Inc, Groton, Connecticut, United States of America
⨯
Richard Chambers,

Affiliation Pfizer Inc, Collegeville, Philadelphia, United States of America
⨯
Seema Haider,

Affiliation Pfizer Inc, Groton, Connecticut, United States of America
⨯
Kit Simpson

Affiliation Medical University of South Carolina, Charleston, South Carolina, United States of America
⨯

Reader Comments (0)

Protease inhibitor therapy
Is the Subject Area "Protease inhibitor therapy" applicable to this article?

Thanks for your feedback.
Antiretroviral therapy
Is the Subject Area "Antiretroviral therapy" applicable to this article?

Thanks for your feedback.
Drug therapy
Is the Subject Area "Drug therapy" applicable to this article?

Thanks for your feedback.
HIV
Is the Subject Area "HIV" applicable to this article?

Thanks for your feedback.
Health economics
Is the Subject Area "Health economics" applicable to this article?

Thanks for your feedback.
Antiretrovirals
Is the Subject Area "Antiretrovirals" applicable to this article?

Thanks for your feedback.
Inpatients
Is the Subject Area "Inpatients" applicable to this article?

Thanks for your feedback.
Total cell counting
Is the Subject Area "Total cell counting" applicable to this article?

Thanks for your feedback.